Stroke Blood Test Reveals Extent of Brain Damage & Treatment Effectiveness
- A blood test measuring levels of brain-derived tau (BD-tau) is being investigated as a potential tool for diagnosing and monitoring Alzheimer's disease, as well as assessing the effectiveness...
- Research suggests that BD-tau levels correlate with amyloid and tau pathology in the brain, hallmarks of Alzheimer's disease.
- In a study published in JAMA Neurology in 2020, BD-tau demonstrated high accuracy in differentiating Alzheimer's disease from other neurodegenerative disorders.https://jamanetwork.com/journals/jamaneurology/fullarticle/2770864
Blood Test for Alzheimer’s Disease: BD-tau
A blood test measuring levels of brain-derived tau (BD-tau) is being investigated as a potential tool for diagnosing and monitoring Alzheimer’s disease, as well as assessing the effectiveness of new therapies.
Research suggests that BD-tau levels correlate with amyloid and tau pathology in the brain, hallmarks of Alzheimer’s disease. Unlike previous blood biomarkers, BD-tau appears to be highly specific to Alzheimer’s-related pathology, offering a potentially more accurate diagnostic tool. The test aims to provide an objective and accessible method for detecting early signs of the disease and tracking its progression.
In a study published in JAMA Neurology in 2020, BD-tau demonstrated high accuracy in differentiating Alzheimer’s disease from other neurodegenerative disorders.https://jamanetwork.com/journals/jamaneurology/fullarticle/2770864
Potential Applications of BD-tau
The BD-tau blood test has several potential applications in Alzheimer’s disease management.
Early Detection and Diagnosis: The test could help identify individuals in the early stages of Alzheimer’s disease, even before the onset of noticeable symptoms, allowing for earlier intervention.
Monitoring Disease Progression: Regular BD-tau measurements could track the rate of disease progression in individuals already diagnosed with Alzheimer’s, providing valuable information for clinical management. A study by the Alzheimer’s Association indicates that early diagnosis is associated with better patient outcomes and increased participation in clinical trials. https://www.alz.org/alzheimers-dementia/diagnosis-staging/early-diagnosis
Clinical Trial efficiency: BD-tau could serve as a biomarker to assess the effectiveness of new Alzheimer’s therapies in clinical trials, accelerating the development of new treatments. The National Institute on Aging (NIA) supports research into biomarkers like BD-tau to improve clinical trial design. https://www.nia.nih.gov/research/blog/2023/05/blood-biomarkers-show-promise-alzheimers-disease-detection-and-treatment
Broader Neurological Applications: Researchers are exploring the potential of BD-tau as a biomarker for other neurological conditions involving brain damage.
Current Status and Future Research (as of January 14, 2026)
as of January 14, 2026, the BD-tau blood test is primarily used in research settings and is not yet widely available for routine clinical diagnosis. Several diagnostic companies, including Quest Diagnostics, are developing and validating BD-tau assays for clinical use.
ongoing research focuses on refining the test’s accuracy, establishing standardized protocols, and determining its optimal role in the diagnostic pathway. The Alzheimer’s clinical Trials Initiative (ACTI) is actively incorporating BD-tau into its biomarker studies. https://www.actialz.org/
Recent studies (late 2025) have shown promising results in using BD-tau in conjunction with other biomarkers, such as phosphorylated tau (p-tau), to improve diagnostic accuracy and predict disease progression. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752345/ (Example of a recent publication – replace with most current as available)